This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walker, E. B. Articles by Urba, W. J. Search for Related Content PubMed PubMed Citation Articles by Walker, E. B. Articles by Urba, W. J.

gp100_209–2M Peptide Immunization of Human Lymphocyte Antigen-A2⁺ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8⁺ T Cells

¹ Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon; ² Department of Molecular and Microbiology and Immunology, Oregon Heath and Science University, Portland, Oregon; ³ Becton Dickinson Biosciences, San Jose, California; ⁴ Ludwig Institute for Cancer Research-Division of Oncology-Immunology, Lausanne, Switzerland; and ⁵ DMS–National Cancer Institute, Frederick, Maryland

Thirty-five HLA-A2⁺ patients with completely resected stage I-III melanoma were vaccinated multiple times over 6 months with a modified melanoma peptide, gp100_209–2M, emulsified in Montanide adjuvant. Direct ex vivo gp100_209–2M tetramer analysis of pre- and postvaccine peripheral blood mononuclear cells (PBMCs) demonstrated significant increases in the frequency of tetramer⁺ CD8⁺ T cells after immunization for 33 of 35 evaluable patients (median, 0.36%; range, 0.05–8.9%). Ex vivo IFN- cytokine flow cytometry analysis of postvaccine PBMCs after brief gp100_209–2M in vitro activation showed that for all of the patients studied tetramer⁺ CD8⁺ T cells produced IFN-; however, some patients had significant numbers of tetramer⁺ IFN-^- CD8⁺T cells suggesting functional anergy. Additionally, 8 day gp100_209–2M in vitro stimulation (IVS) of pre- and postvaccine PBMCs resulted in significant expansion of tetramer⁺ CD8⁺ T cells from postvaccine cells for 34 patients, and these IVS tetramer⁺ CD8⁺ T cells were functionally responsive by IFN- cytokine flow cytometry analysis after restimulation with either native or modified gp100 peptide. However, correlated functional and phenotype analysis of IVS-expanded postvaccine CD8⁺ T cells demonstrated the proliferation of functionally anergic gp100_209–2M- tetramer⁺ CD8⁺ T cells in several patients and also indicated interpatient variability of gp100_209–2M stimulated T-cell proliferation. Flow cytometry analysis of cryopreserved postvaccine PBMCs from representative patients showed that the majority of tetramer⁺ CD8+ T cells (78.1 ± 4.2%) had either an "effector" (CD45 RA⁺/CCR7^-) or an "effector-memory" phenotype (CD45RA^-/CCR7^-). Notably, analysis of PBMCs collected 12–24 months after vaccine therapy demonstrated the durable presence of gp100_209–2M-specific memory CD8⁺ T cells with high proliferation potential. Overall, this report demonstrates that after vaccination with a MHC class I-restricted melanoma peptide, resected nonmetastatic melanoma patients can mount a significant antigen-specific CD8⁺ T-cell immune response with a functionally intact memory component. The data further support the combined use of tetramer binding and functional assays in correlated ex vivo and IVS settings as a standard for immunomonitoring of cancer vaccine patients.

This article has been cited by other articles:

				E. B. Walker, W. Miller, D. Haley, K. Floyd, B. Curti, and W. J. Urba Characterization of the Class I-Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free Vaccine-draining Lymph Nodes and Peripheral Blood Clin. Cancer Res., April 1, 2009; 15(7): 2541 - 2551. [Abstract] [Full Text] [PDF]

				E. B. Walker, D. Haley, U. Petrausch, K. Floyd, W. Miller, N. Sanjuan, G. Alvord, B. A. Fox, and W. J. Urba Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization Clin. Cancer Res., August 15, 2008; 14(16): 5270 - 5283. [Abstract] [Full Text] [PDF]

				C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X.-x. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin, and J. S. Yu Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients Cancer Res., July 15, 2008; 68(14): 5955 - 5964. [Abstract] [Full Text] [PDF]

				M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor Cancer Res., July 1, 2008; 68(13): 5206 - 5215. [Abstract] [Full Text] [PDF]

				O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape Cancer Res., May 1, 2008; 68(9): 3450 - 3457. [Abstract] [Full Text] [PDF]

				D. Atanackovic, N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming PNAS, February 5, 2008; 105(5): 1650 - 1655. [Abstract] [Full Text] [PDF]

				D. J. Powell Jr., A. Felipe-Silva, M. J. Merino, M. Ahmadzadeh, T. Allen, C. Levy, D. E. White, S. Mavroukakis, R. J. Kreitman, S. A. Rosenberg, et al. Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo J. Immunol., October 1, 2007; 179(7): 4919 - 4928. [Abstract] [Full Text] [PDF]

				G. P. Linette, D. Zhang, F. S. Hodi, E. P. Jonasch, S. Longerich, C. P. Stowell, I. J. Webb, H. Daley, R. J. Soiffer, A. M. Cheung, et al. Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity Clin. Cancer Res., November 1, 2005; 11(21): 7692 - 7699. [Abstract] [Full Text] [PDF]